Barclays raised the firm’s price target on Incyte (INCY) to $117 from $116 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Profit Outlook Threatened by Emerging U.S. ‘Most Favored Nation’ Drug Pricing Policies
- Incyte price target raised to $102 from $94 at Morgan Stanley
- Incyte price target raised to $120 from $119 at Stifel
- Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target
- Incyte Earnings Call Highlights Growth Beyond Jakafi